alpha-aminopyridine has been researched along with Cognitive Dysfunction in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 12 (70.59) | 2.80 |
| Authors | Studies |
|---|---|
| Arahata, Y; Bundo, M; Ikenuma, H; Ito, K; Iwata, K; Kato, T; Kimura, Y; Nakamura, A; Nihashi, T; Okamura, N; Sakurai, K; Sakurai, T; Suzuki, K; Takeda, A; Washimi, Y; Yamaoka, A; Yanai, K | 1 |
| Choe, YS; Chun, MY; Jang, H; Jeong, JH; Kim, HJ; Kim, JS; Kim, YJ; Lee, J; Moon, SH; Na, DL; Oh, JS; Oh, M; Oh, SJ; Roh, JH; Seo, SW; Woo, SY | 1 |
| Bhat, A; Bishir, M; Chang, SL; Chidambaram, SB; Pandi-Perumal, SR | 1 |
| Liu, C; Liu, P; Peng, S; Shi, X; Wang, J; Zhang, D; Zhang, Y; Zhuang, L | 1 |
| Garabadu, D; Goyal, A | 1 |
| Bindu, M; Murugesan, A; Sugin, LJS; Sunil, KN | 1 |
| Ffytche, D; Gilleen, J; Kerins, S; Lahu, G; Mehta, MA; Nottage, J; Ogrinc, F; Shergill, SS; Tsai, M; Uz, T; Valdearenas, L; Williams, SC; Yakub, F | 1 |
| Hong, JS; Hou, L; Jing, L; Li, S; Peng, B; Ruan, Z; Wang, Q; Zhang, D; Zhang, X; Zhao, J | 1 |
| Gilleen, J; Hawkins, PC; Livingston, NR; Mehta, MA; Shergill, SS; Valdearenas, L; Ye, R | 1 |
| Kim, JS; Kim, M; Kim, SJ; Oh, JS; Oh, M; Oh, SJ; Park, JE; Roh, JH; Seo, SW; Shim, WH; Yun, J | 1 |
| Ashour, NH; El Sayed, NS; El-Tanbouly, DM; Khattab, MM | 1 |
| Bonato, JM; de Oliveira, RMW; Kunieda, JKC; Milani, H; Prickaerts, J; Schepers, M; Vanmierlo, T; Vilhena, ER | 1 |
| Comley, RA; Gauthier, S; Guiot, MC; Guo, Q; Harada, R; Kang, MS; Massarweh, G; Mathotaarachchi, S; Ng, KP; Okamura, N; Pascoal, TA; Rosa-Neto, P; Shin, M; Soucy, JP; Therriault, J | 1 |
| Cho, J; Furumoto, S; Ido, T; Jeong, HJ; Kang, H; Kang, JM; Lee, H; Lee, KM; Lee, SY; Lee, YB; Na, DL; Noh, Y; Okamura, N; Park, KH; Seo, S; Seong, JK; Shin, DH; Villemagne, VL; Woo, SH; Yanai, K; Yeon, BK | 1 |
| Acharya, MM; Allen, BD; Chmielewski, NN; Giedzinski, E; Hefferan, M; Johe, KK; Limoli, CL; Lu, C; Quach, D | 1 |
| Feng, H; He, B; He, W; Li, S; Wang, C; Wei, M; Wu, X; Zeng, Z | 1 |
| Ducruet, AF; Lawton, MT; Qiu, S; Sheth, KN; Shi, E; Shi, K | 1 |
1 review(s) available for alpha-aminopyridine and Cognitive Dysfunction
| Article | Year |
|---|---|
Roflumilast: A potential drug for the treatment of cognitive impairment?
Topics: Aminopyridines; Animals; Benzamides; Cognitive Dysfunction; Cyclopropanes; Humans; Memory; Phosphodiesterase 4 Inhibitors | 2020 |
4 trial(s) available for alpha-aminopyridine and Cognitive Dysfunction
| Article | Year |
|---|---|
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Cognition; Cognitive Dysfunction; Humans; Positron-Emission Tomography; Quinolines | 2022 |
The effects of roflumilast, a phosphodiesterase type-4 inhibitor, on EEG biomarkers in schizophrenia: A randomised controlled trial.
Topics: Adult; Aminopyridines; Benzamides; Cognition; Cognitive Dysfunction; Cross-Over Studies; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Double-Blind Method; Drug Monitoring; Electroencephalography; Evoked Potentials; Female; Humans; Male; Mental Processes; Phosphodiesterase 4 Inhibitors; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome | 2021 |
Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia.
Topics: Adult; Aged; Aminopyridines; Benzamides; Cognitive Dysfunction; Cross-Over Studies; Cyclopropanes; Dorsolateral Prefrontal Cortex; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Phosphodiesterase 4 Inhibitors; Prefrontal Cortex; Schizophrenia | 2021 |
Combination of automated brain volumetry on MRI and quantitative tau deposition on THK-5351 PET to support diagnosis of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aminopyridines; Brain; Cognitive Dysfunction; Diagnosis, Differential; Female; Healthy Volunteers; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Imaging; Positron-Emission Tomography; Prospective Studies; Quinolines; Radiopharmaceuticals; tau Proteins | 2021 |
12 other study(ies) available for alpha-aminopyridine and Cognitive Dysfunction
| Article | Year |
|---|---|
Patterns of Distribution of 18F-THK5351 Positron Emission Tomography in Alzheimer's Disease Continuum.
Topics: Aged; Alzheimer Disease; Aminopyridines; Amnesia; Aniline Compounds; Brain; Cognitive Dysfunction; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Positron-Emission Tomography; Quinolines; Radiopharmaceuticals; Severity of Illness Index; tau Proteins; Thiazoles | 2022 |
Roflumilast, a Phosphodiesterase-4 Inhibitor, Ameliorates Sleep Deprivation-Induced Cognitive Dysfunction in C57BL/6J Mice.
Topics: Aminopyridines; Amyloid beta-Peptides; Animals; Benzamides; Brain-Derived Neurotrophic Factor; Cognitive Dysfunction; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Hippocampus; Mice; Mice, Inbred C57BL; Phosphodiesterase 4 Inhibitors; Sleep Deprivation; Synapsins | 2022 |
Suppression of phosphodiesterase IV enzyme by roflumilast ameliorates cognitive dysfunction in aged rats after sevoflurane anaesthesia via PKA-CREB and MEK/ERK pathways.
Topics: Aminopyridines; Anesthesia; Animals; Benzamides; Cognitive Dysfunction; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Hippocampus; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Phosphodiesterase Inhibitors; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Sevoflurane | 2022 |
Roflumilast attenuates cognitive deficits in estrogen insufficient rats.
Topics: Aminopyridines; Animals; Benzamides; Cognition; Cognitive Dysfunction; Cyclic AMP; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Estrogen Receptor alpha; Estrogens; Female; Ovariectomy; Phenols; Phosphodiesterase 4 Inhibitors; Pyrazoles; Rats; Rats, Wistar | 2020 |
Microglial activation contributes to cognitive impairments in rotenone-induced mouse Parkinson's disease model.
Topics: Aminopyridines; Animals; Cognitive Dysfunction; Insecticides; Male; Mice; Mice, Inbred C57BL; Microglia; Minocycline; Parkinsonian Disorders; Pyrroles; Rotenone | 2021 |
Roflumilast ameliorates cognitive deficits in a mouse model of amyloidogenesis and tauopathy: Involvement of nitric oxide status, Aβ extrusion transporter ABCB1, and reversal by PKA inhibitor H89.
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cognitive Dysfunction; Cyclopropanes; Disease Models, Animal; Hippocampus; Isoquinolines; Male; Mice; Nitric Oxide; Phosphodiesterase 4 Inhibitors; Protein Kinase Inhibitors; Streptozocin; Sulfonamides; Tauopathies | 2021 |
Positive effects of roflumilast on behavior, neuroinflammation, and white matter injury in mice with global cerebral ischemia.
Topics: Aminopyridines; Animals; Arginase; Behavior, Animal; Benzamides; Brain Ischemia; Calcium-Binding Proteins; Cognitive Dysfunction; Cyclopropanes; Hippocampus; Mice; Microfilament Proteins; Microglia; Neuroinflammatory Diseases; Neuroprotective Agents; Phosphodiesterase 4 Inhibitors; Recovery of Function; Treatment Outcome; White Matter | 2021 |
Monoamine oxidase B inhibitor, selegiline, reduces
Topics: Aged; Alzheimer Disease; Aminopyridines; Autoradiography; Binding, Competitive; Brain; Cognitive Dysfunction; Drug Interactions; Female; Fluorine Radioisotopes; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Positron-Emission Tomography; Quinolines; Radiopharmaceuticals; Selegiline; Supranuclear Palsy, Progressive; tau Proteins | 2017 |
Tau positron emission tomography using [
Topics: Aged; Alzheimer Disease; Aminopyridines; Amnesia; Brain; Cognitive Dysfunction; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Positron-Emission Tomography; Quinolines; Radiopharmaceuticals; Severity of Illness Index; tau Proteins | 2017 |
Remediation of Radiation-Induced Cognitive Dysfunction through Oral Administration of the Neuroprotective Compound NSI-189.
Topics: Administration, Oral; Aminopyridines; Animals; Cognition; Cognitive Dysfunction; Conditioning, Psychological; Cranial Irradiation; Fear; Hippocampus; Neuroprotective Agents; Organ Size; Piperazines; Radiation Injuries, Experimental; Rats; Recognition, Psychology | 2018 |
Roflumilast ameliorates cognitive impairment in APP/PS1 mice via cAMP/CREB/BDNF signaling and anti-neuroinflammatory effects.
Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Animals; Benzamides; Brain-Derived Neurotrophic Factor; Cognitive Dysfunction; Cyclic AMP; Cyclopropanes; Disease Models, Animal; Male; Memory; Mice, Transgenic; Nootropic Agents; Phosphodiesterase 4 Inhibitors | 2019 |
Chronic inflammation, cognitive impairment, and distal brain region alteration following intracerebral hemorrhage.
Topics: Aminopyridines; Animals; Brain; Cerebral Hemorrhage; Cognition; Cognitive Dysfunction; Disease Models, Animal; Fingolimod Hydrochloride; Flow Cytometry; Hippocampus; Inflammation; Male; Mice; Mice, Inbred C57BL; Microglia; Neuroimaging; Neuronal Plasticity; Pyrroles; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 2019 |